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Our aim was to longitudinally investigate menarche timing
and menstrual cycle (MC) pattern during the first five
gynaecological years in 101 girls with idiopathic central
precocious puberty (CPP) who had been treated with
gonadotropin-releasing hormone agonists (GnRHa) for at
least two years. Our girls received Decapeptyl Depot
(60 μg/Kg) every 28 days from a chronological age (CA)
of 7.8 years (range 3.3–8.9) and for 24–96 months (median
43) till the age of 11.3 years (range 9.6–13.8). All of them
exhibited adequate compliance with the GnRHa regimen, as
elsewhere reported [1].
Bone age (BA) was evaluated both at entry and at the
end of GnRHa therapy and was, respectively, 10 and
13.6 years.
From therapy withdrawal onwards the girls were
semestrally re-examined until menarche. Menarcheal age
(MA) was assessed by a semistructured interview and
calculated by decimal year according to birthday.
Mothers’ MAs were confirmed by patients’ mothers.
After menarche the patients were regularly re-evaluated
at 1-year intervals for at least five years in order to get
information about MC pattern. Menstruation frequency was
determined from monthly diaries maintained by girls and
their families.
Definitions of MC pattern [6] include: (a) secondary
amenorrhea, the absence of menstruation for 180 days or
more; (b) oligomenorrhea (OM), average length of MC
between 42 and 180 days; (c) polymenorrhea (PM), average
length of MC 21 days or less; and (d) regular or irregular
MC (RMC or IMC), average length of MC between 22 and
41 days; either none or a single MC with a length of less
than 22 or more than 41 days during the past year (RMC);
two or more MC with a length of less than 22 or more than
41 days during the past year (IMC).
For statistical purposes, χ2 linear trend analysis was
performed to study the effect of gynaecological age (GA)
on the prevalence of OM, PM, and both RMC and IMC.
Correlation regression analysis was used to evaluate the
influence of other factors on menarche timing.
Median MA was 12.6 years (range 10.6–15.2), i.e.
significantly higher (p<0.0005) with respect to that of their
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mothers (11.6; range 8–14). MA in our patients was
positively related to both CA ( x=12.5, y=11.2, r 0.51,
p<0.001) and BA at the end of treatment ( x=12.5, y=12.8,
r 0.32, p<0.01). Moreover, it was significantly associated
with therapy duration (x=12.5, y=44,5, r 0.42, p<0.001).
Time duration between therapy withdrawal and menarche
was 14.0 months (range 3–42). This time interval nega-
tively correlated with both CA (x=15.6, y=7.5, r −0.56,
p<0.001) and BA (x=15.6, y=9.9, r −0.30, p<0.01) at the
time of therapy withdrawal and also with treatment duration
(x=15.6, y=44.5, r −0.34, p<0.01).
The history of MC patterns showed both a progressive
decrease of OM prevalence (χ2 47.8, p<0.0001) and a
concomitant progressive increase of RMC and IMC
(χ2 54.5, p<0.0001) by increasing GA (Table 1). No cases
of secondary amenorrhea were recorded during the entire
follow-up and only a few cases of polymenorrhea were
found during the first two gynaecological years (Table 1).
Although Depot preparations of GnRHa have been the
choice treatment for CPP since the mid 1980s, their long-
term effects on gonadal function are controversial: one
study reported an increased prevalence of polycystic
ovaries (PCO) in GnRHa treated girls [2], whereas PCO-
like ovaries were seen only rarely or not at all in a more
recent study [3]. According to our results MC abnormalities
are observed only during the first gynaecological years and
their prevalence decreases with increasing GA, a pattern
which is also frequently found in normal adolescents [5].
These data confirm that GnRHa therapy has no long-term
detrimental effects on MC of girls with CPP even though
prolonged over time [4]. On the contrary, in our patients
time to menarche following GnRHa withdrawal inversely
correlated with treatment duration. An unexpected finding
of our study is that MA of our patients was higher than MA
of the respective mothers and unrelated to it, contrary to
what is generally reported in various other conditions [3].
The relationship between MA of the girls and their mothers,
in fact, is known to persist under all circumstances, with
few exceptions [3]. This confirms that GnRHa therapy is
able to modify the natural course of puberty events in girls
with CPP.
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Table 1 Distribution (%) of menstrual cycle (MC) patterns of our 101 patients by gynaecological age
Gynaecological age (months)
1–12 13–24 25–36 37–48 49–60
Regular and irregular MC 49.5 65.3 85.2 92.1 96.0
Oligomenorrhea 46.5 33.7 14.8 7.9 4.0
Polymenorrhea 4.0 1.0 0 0 0
Secondary amenorrhea 0 0 0 0 0
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